M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission:: relevance to the pathophysiology and treatment of related central nervous system pathologies

被引:139
作者
Tzavara, ET
Bymaster, FP
Davis, RJ
Wade, MR
Perry, KW
Wess, J
McKinzie, DL
Felder, C
Nomikos, GG
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
[2] NIDDKD, Bioorgan Chem Lab, Bethesda, MD 20892 USA
关键词
acetylcholine; microdialysis; dopamine; psychostimulants;
D O I
10.1096/fj.04-1575fje
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Dopaminergic dysfunction is an important pathogenetic factor for brain pathologies such as Parkinson's disease, ADHD, schizophrenia, and addiction as well as for metabolic disorders and anorexia. Dopaminergic neurons projecting from the midbrain to forebrain regions, such as the nucleus accumbens and the prefrontal cortex, regulate motor and cognitive functions and coordinate the patterned response of the organism to sensory, affective, and rewarding stimuli. In this study, we showed that dopaminergic neurotransmission is highly dependent on M-4 cholinergic muscarinic receptor function. Using in vivo microdialysis, we found elevated dopamine (DA) basal values and enhanced DA response to psychostimulants in the nucleus accumbens of M-4 knockout mice. We also demonstrated impaired homeostatic control of cholinergic activity that leads to increased basal acetylcholine efflux in the midbrain of these animals. Thus, loss of M-4 muscarinic receptor control of cholinergic function effectuates a state of dopaminergic hyperexcitability. This may be responsible for pathological conditions, in which appetitive motivation as well as affective and cognitive processing is impaired. We propose that M-4 receptor agonists could represent an innovative strategy for the treatment of pathologies associated with hyperdopaminergia.
引用
收藏
页码:1410 / +
页数:18
相关论文
共 57 条
[1]   Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia [J].
Basile, AS ;
Fedorova, I ;
Zapata, A ;
Liu, XG ;
Shippenberg, T ;
Duttaroy, A ;
Yamada, M ;
Wess, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (17) :11452-11457
[2]  
BERNARD V, 1992, J NEUROSCI, V12, P3591
[3]   Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease [J].
Bodick, NC ;
Offen, WW ;
Levey, AI ;
Cutler, NR ;
Gauthier, SG ;
Satlin, A ;
Shannon, HE ;
Tollefson, GD ;
Rasmussen, K ;
Bymaster, FP ;
Hurley, DJ ;
Potter, WZ ;
Paul, SM .
ARCHIVES OF NEUROLOGY, 1997, 54 (04) :465-473
[4]   Muscarinic Receptors as a Target for Drugs Treating Schizophrenia [J].
Bymaster, Frank P. ;
Felder, Christian ;
Ahmed, Saeed ;
McKinzie, David .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2002, 1 (02) :163-181
[5]   Acetylcholine-mediated modulation of striatal function [J].
Calabresi, P ;
Centonze, D ;
Gubellini, P ;
Pisani, A ;
Bernardi, G .
TRENDS IN NEUROSCIENCES, 2000, 23 (03) :120-126
[6]  
Caulfield MP, 1998, PHARMACOL REV, V50, P279
[7]  
Chapman CA, 1997, NEUROSCIENCE, V76, P177
[8]   BASAL ACETYLCHOLINE-RELEASE IN FREELY MOVING RATS DETECTED BY ONLINE TRANS-STRIATAL DIALYSIS - PHARMACOLOGICAL ASPECTS [J].
DAMSMA, G ;
WESTERINK, BHC ;
DEBOER, P ;
DEVRIES, JB ;
HORN, AS .
LIFE SCIENCES, 1988, 43 (14) :1161-1168
[9]   BIOCHEMICAL EVIDENCE FOR PRESENCE OF PRESYNAPTIC RECEPTORS ON DOPAMINERGIC NERVE-TERMINALS [J].
DEBELLEROCHE, J ;
BRADFORD, HF .
BRAIN RESEARCH, 1978, 142 (01) :53-68
[10]   MODULATORY FUNCTIONS OF NEUROTRANSMITTERS IN THE STRIATUM - ACH/DOPAMINE/NMDA INTERACTIONS [J].
DICHIARA, G ;
MORELLI, M ;
CONSOLO, S .
TRENDS IN NEUROSCIENCES, 1994, 17 (06) :228-233